Madiha Derouazi

Directeur Technique/Scientifique/R&D chez AC IMMUNE SA

Fortune : 14 764 $ au 31/05/2024

51 ans

Health Technology

Consumer Services

Postes actifs de Madiha Derouazi

Sociétés	Poste	Début	Fin
AC IMMUNE SA	Directeur Technique/Scientifique/R&D	01/01/2024	-
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Directeur/Membre du Conseil	03/09/2012	-
	Directeur Général	03/09/2012	-
	Fondateur	03/09/2012	-

Sociétés	Poste	Début	Fin

Technical University of Berlin	Graduate Degree
Swiss Federal Institute of Technology	Doctorate Degree

Internationale

Suisse	3
Allemagne	3

Opérationnelle

Sectorielle

Health Technology	3
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
AC IMMUNE SA	Health Technology

Entreprise privées	1
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Health Technology

Entreprise privées

Health Technology